Published in final edited form as:

Int Urogynecol J. 2018 December ; 29(12): 1785–1795. doi:10.1007/s00192-018-3683-6.

THE URINARY MICROBIOME IN WOMEN WITH MIXED URINARY INCONTINENCE COMPARED TO SIMILARLY AGED CONTROLS

Yuko M. Komesu, MD¹, Holly E. Richter, MD PhD², Benjamin Carper, MS³, Darrell L. Dinwiddie, PhD⁴, Emily S. Lukacz, MD⁵, Nazema Y. Siddiqui, MD, MHS⁶, Vivian W. Sung, MD⁷, Halina M. Zyczynski, MD⁸, Beri Ridgeway, MD⁹, Rebecca G. Rogers, MD^{1,10}, Lily A. Arya, MD¹¹, Donna Mazloomdoost, MD¹², and Marie G. Gantz, PhD³ For the Pelvic Floor Disorders Network

¹Obstetrics & Gynecology, University of New Mexico Health Sciences Center, Albuquerque, NM, United States

²Obstetrics & Gynecology, University of Alabama at Birmingham, Birmingham, AL, United States

³Social, Statistical & Environmental Sciences, RTI International, Research Triangle Park, NC, United States

⁴Pediatrics and Clinical Translational Science Center, University of New Mexico Health Sciences Center, Albuquerque, NM, United States

⁵Department of Reproductive Medicine, University of California San Diego, San Diego, CA, United States

⁶Obstetrics & Gynecology, Duke University, Durham, NC, United States

Contact Information: Yuko M Komesu MD University of New Mexico Health Sciences, Center Department of Obstetrics and Gynecology, MSC 10 5580 1 University of New Mexico, Albuquerque, New Mexico 87131-0001, U.S.A., Phone: +1-505-272-9712 Fax: +1-505-272-1336, ykomesu@salud.unm.edu.

Presentation of information in this manuscript: Oral poster presented at the Pelvic Floor Disorders Week Conference (sponsored by the American Urogynecologic Society), October 5, 2017, Providence, Rhode Island; e-oral poster presented at the International Continence Society annual meeting, Florence, Italy, September 13, 2017.

Authors Contribution to the Manuscript:

Yuko Komesu: Protocol/project development, data collection, data interpretation, manuscript writing/editing

Holly Richter: Protocol/project development, data collection, data interpretation, manuscript writing/editing

Benjamin Carper: Data analysis & interpretation, manuscript writing/editing

Darrell Dinwiddie: Protocol/project development, Specimen processing/DNA extraction/16S sequencing, Data interpretation, manuscript writing/editing

Emily S. Lukacz: Protocol/project development, data collection, data interpretation, manuscript writing/editing

Nazema Y. Siddiqui: Protocol/project development, data collection, data interpretation, manuscript writing/editing

Vivian W. Sung: Protocol/project development, data collection, data interpretation, manuscript writing/editing

Halina M. Zyczynski: Protocol/project development, data collection, data interpretation, manuscript writing/editing

Beri Ridgeway: Protocol/project development, data collection, data interpretation, manuscript writing/editing

Rebecca G. Rogers: Protocol/project development, data collection, data interpretation, manuscript writing/editing

Lily A. Arya: Protocol/project development, data collection, data interpretation, manuscript writing/editing

Donna Mazloomdoost: Data interpretation, manuscript writing/editing

Marie Gantz: Protocol/project development, Data analysis & interpretation, manuscript writing/editing

Author's Potential Conflicts of Interest/Disclosures: Yuko Komesu MD: Co-PI Grant 1R01AT007171, National Center Complementary and Integrative Health, NIH and "Funding Source" above. Holly Richter PhD, MD: UpToDate, Renovia. Benjamin Carper: None. Darrell L. Dinwiddie PhD: None. Emily S. Lukacz MD: AMS/Astora, Axonics, Boston Scientific, Uroplasty/Coloplast, UpToDate. Nazema Y. Siddiqui MD: Medtronic. Vivian W. Sung MD: None. Halina M. Zyczynski MD: AUGS Board. Beri Ridgeway MD: Coloplast, Ethicon. Rebecca G. Rogers MD: UpToDate, ABOG Board member, Transform Trial, International Urogynecology Journal. Lily A. Arya MD: None. Donna Mazloomdoost MD: None. Marie G. Gantz PhD: None

⁷Obstetrics & Gynecology, Alpert Medical School of Brown University, Providence, RI, United States

⁸Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Research Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States

⁹Obstetrics & Gynecology, Cleveland Clinic, Cleveland, OH, United States

¹⁰Obstetrics & Gynecology, Dell Medical School University of Texas Austin, Austin TX, United States

¹¹Obstetrics & Gynecology, University of Pennsylvania School of Medicine, Philadelphia, PA, United States

¹²Gynecologic Health and Disease Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) National Institutes of Health (NIH), Bethesda, MD, United States

Abstract

Introduction & Hypothesis—Previous studies have suggested that women with urinary incontinence have an altered urinary microbiome. We hypothesized that the microbiome in women with mixed urinary incontinence (MUI) differed from controls and tested this hypothesis using bacterial gene sequencing techniques.

Methods—This multicenter study compared the urinary microbiome in women with MUI and similarly aged controls. Catheterized urine samples were obtained; v4–6 regions of the 16S rRNA gene were sequenced to identify bacteria. Bacterial predominance (> 50% of an individual's genera) was compared between MUI and controls. Bacterial sequences were categorized into “community-types” using Dirichlet multinomial mixture (DMM) methods. Generalized linear mixed models predicted MUI/control status based on clinical characteristics and community-type. Post-hoc analyses were performed in women <51 and ≥51 years. Sample size estimates required 200 samples to detect a 20% difference in *Lactobacillus* predominance with $P < .05$.

Results—Of 212 samples, 97.6% were analyzed (123 MUI/84 controls, mean age 53 ± 11 years). Overall *Lactobacillus* predominance did not differ between MUI and controls (45/123=36.6% vs. 36/84=42.9%, $P=0.36$). DMM analyses revealed six community-types; communities differed by age ($P=0.001$). A *High-Lactobacillus* (89.2% *Lactobacillus*) community had a greater proportion of controls (19/84=22.6%, MUI 11/123=8.9%). Overall, bacterial community-types did not differ in MUI and controls. However, post-hoc analysis of women <51 years found that bacterial community-types distinguished MUI from controls ($P=0.041$); *Moderate-Lactobacillus* (aOR 7.78, CI 1.85–32.62) and *Mixed* (aOR 7.10, CI 1.32–38.10) community-types were associated with MUI. Community-types did not differentiate MUI and controls in women ≥51 years ($P=0.94$).

Conclusions—Women with MUI and controls did not differ in overall *Lactobacillus* predominance. In younger women, urinary bacterial community-types differentiated MUI from controls.

Keywords

mixed urinary incontinence; female urinary microbiome (FUM); urinary microbiome; lactobacillus; 16S rRNA gene sequencing; menopausal status

Introduction

Mixed urinary incontinence (MUI) is the involuntary leakage of urine associated with both urgency and with stress provocation. Of all incontinence types, MUI is the most refractory to treatment, its pathophysiology the least understood and therapies the least standardized, posing significant treatment challenges [1]. Women with MUI face a therapeutic dilemma because of the dual nature of their condition; treatment of stress urinary incontinence (SUI) symptoms may exacerbate urgency while treatment of urgency urinary incontinence (UII) symptoms may worsen SUI. The study, Effects of Surgical Treatment Enhanced with Exercise for Mixed Urinary Incontinence (ESTEEM), was designed to compare stress, urgency and MUI symptom outcomes in an MUI population treated with surgery alone versus surgery and behavioral/pelvic floor therapy [2]. The ESTEEM study's population provided a singular opportunity to evaluate the urinary microbiome as a biologically plausible contributor to MUI.

Prior work has established that the female urinary microbiome is associated with UII [3,4,5]. With the advent of precise bacterial DNA testing, it is clear that a female urinary microbiome exists and that it may have a role in UII treatment response [3,5]. As the urinary microbiome may have a role in UII, the question arises whether the urinary microbiome may also play a role in MUI, an even more severe form of incontinence that includes UII. The current study builds on the existing data regarding the relationship between the urinary microbiome and UII, and expands its scope to include those participants with MUI. This is a clinically relevant, as MUI is enigmatic and difficult to treat. For example, improvement of the UII component of MUI following stress incontinence surgery has never been clearly understood. If change in the MUI microbiome occurs, particularly in the microbiota associated with UII, clinicians would then have a potential explanation for improvement of the UII component of MUI following stress incontinence surgery. This MUI microbiome study's over-arching goal is to provide insight into MUI's underlying pathophysiology and to gain insight into MUI's varying clinical responses following treatment.

In the current study, we evaluated the urinary microbiome in women with MUI at baseline compared to asymptomatic, similarly aged controls. Subsequent work may determine whether MUI microbiome characteristics have a role in MUI treatment response. Based on previous studies that found that women with UII have a more diverse microbiome and decreased *Lactobacillus* compared to controls [3,4], we hypothesized that the microbiome of women with MUI differed from asymptomatic controls in both overall *Lactobacillus* predominance and in microbial community-types.

Methods

Study Population & Design

This multi-site, IRB-approved, observational study evaluated the urinary microbiome in women with and without MUI. The methodology for this study has been previously published [6]. We excluded patients who had used oral or intravenous antibiotics within the last month, who had used vaginal antibiotics within the prior 7 days, who were currently using vaginal probiotics or spermicides. Furthermore, we discouraged participants from engaging in vaginal intercourse/douching/using vaginal sprays or wipes for 48 hours prior to study visits and specimens were collected at least 48 hours following cessation of menses. MUI participants consisted of a subset of women enrolled in a randomized trial of MUI treatment comparing efficacy of mid-urethral sling (MUS) surgery alone to MUS surgery and behavioral therapy (NCT# 01959347) [2]. For this supplementary study, we also recruited controls who were of similar age as the MUI cases, as described in the methods paper [6].

Participant characteristics and baseline symptom questionnaire data were obtained including the Urogenital Distress Inventory (UDI) to measure incontinence symptom severity in the MUI participants [7]. The UDI irritative subscale score reflected UUI, the UDI stress subscale score reflected SUI, and the total UDI score reflected MUI severity. The parent study required all MUI participants to have at least “moderate bother” on the UDI for the UUI and SUI items; “Do you usually experience leakage associated with a feeling of urgency...” and “Do you usually experience urinary leakage related to coughing, sneezing, or laughing”. Controls had slight or no incontinence (Incontinence Severity Index scores ≤ 2) and no significant overactive bladder symptoms (Overactive Bladder Awareness Scores < 8) [8,9].

As described previously [6], catheterized urine (5–10 mL) was placed in commercially available tubes containing Assay Assure® DNA protectant after screening negative for infection (absence of dysuria and negative dipstick analysis with nitrites/leukocyte esterase trace). An additional 4 mL of urine were placed in BD Vacutainers® (Sierra Molecular Corporation, Incline Village, NV, USA) for routine urine culture. Tubes were shipped on cold pack to the UNM CTSC Laboratory and received within 24 hours. A clinical laboratory (Tricore Reference Laboratories, Albuquerque, NM, USA) performed routine urine culture and study investigators at the UNM CTSC Laboratory performed immediate DNA extraction. Following DNA extraction, samples were stored at -80°C until completion of specimen collection at all sites. Investigators then performed polymerase chain reaction (PCR) amplification and 16S sequencing.

Laboratory Methods

By design, the study masked laboratory investigators to samples' MUI or control status. DNA isolation procedures, library preparation, sequencing techniques, and analytics have been previously described in detail [6]. As noted in our methods manuscript, variable regions 4–6 of the 16S rRNA gene were amplified by PCR using primers 515F and 1114R with the addition of Illumina® Nextera linker sequences [6,10]. If a single PCR amplicon of

the correct size was not identified during gel electrophoresis (Agilent Bioanalyzer 1000), DNA was re-isolated from remaining urine and the sample was reprocessed. If upon resampling the sample failed again, it was excluded from further processing and analysis. We were unable to recover suitable DNA from five urine samples collected in this study. A second PCR of 10 cycles was used to complete the Illumina adapter sequence and to add dual 8 nucleotide index sequences. Completed sequencing libraries were purified and unused primers were removed using Agencourt AMPure XP beads. After quantification and purity assessment by Qubit fluorometric and gel electrophoresis bioanalysis, (Agilent Bioanalyzer 1000) samples were pooled in equimolar ratios for sequencing.

Sequencing utilized version 3 sequencing chemistry and paired 300bp sequencing reads on the Illumina MiSeq®. Each batch of 96 samples included 88 unique patient samples, six repeated samples to assess sample reproducibility and two negative controls, consisting of a no-DNA extraction control and a no-template PCR control that underwent all PCR, library preparation, and sequencing steps. With the given depth of sequencing in this study, no-template, negative control samples produced a mean of 3,077 (range 2,410–4,242) classified sequencing reads, consequently to ensure a low likelihood of false positive results, we used threshold of >12,000 classified sequencing reads for samples to be included in the final analysis.

Bioinformatics Analysis

Overlapping sequencing reads were combined into a single read and operational taxonomic unit classifications were completed and compared via a high-performance implementation of the Ribosomal Database Project (RDP) Classifier [13] to a curated version of the May 2013 Greengenes database using the Illumina® BaseSpace 16S Metagenomics App (v1.01). Specifically, the Greengenes data was modified to remove 16S sequences with a length was below 1250 bp, entries that had more than 50 wobble bases, and ambiguous epithets and partial classifications. The database includes 16S rRNA sequences representing 33 phyla, 74 classes, 148 orders, 321 families, 1,086 genera, and 6,466 distinct species. The use of the Illumina BaseSpace 16S Metagenomics pipeline was an effort to increase the reproducibility and comparability of our data by using a standardized bioinformatic process that can be easily replicated by other researchers. Urinary bacteria were identified to the genus level this portion of study analysis.

Statistical Analysis

The primary aim of this study was to examine the difference in *Lactobacillus* predominance between MUI and controls. Predominance was defined as a sample in which a specific genus constituted >50% of an individual's taxonomic community. The overall proportions of women with *Lactobacillus* predominance were compared between MUI and controls using chi-square tests. Sample size analysis, with 80% power and alpha of 0.05, indicated that urine specimens from 200 women (120 MUI, 80 Controls) would be required to detect a 20% difference in *Lactobacillus* predominance [6].

The secondary aim was to compare the bacterial taxa between MUI and controls utilizing, Dirichlet Multinomial Mixture (DMM) modeling which identified bacterial communities

across MUI cases and controls [14,15]. The DMM method clustered samples based on the relative abundance of identified microbiota. DMM methodology effectively manages the large data dimensionality associated with microbiome analyses. This facilitated use of sequencing results, in the form of bacterial community-types, and clinical variables in multivariable analyses. Prior to the quantitative analysis, investigators reviewed community-types for clinical relevance. Chi-square testing was used to evaluate whether the DMM community-types differentiated participants with MUI from controls.

Participant characteristics were compared across the DMM community-types in bivariate analysis using chi-square tests and analysis of variance (ANOVA) models. A multivariable generalized linear mixed model with a logit link was constructed to predict MUI or control status based on DMM community-type, with demographic and medical history variables significantly associated with DMM community-type in bivariate analysis ($p < 0.05$), variables associated with MUI versus control status, and other variables of clinical significance as covariates. The model also included a random effect for clinical site.

The study recruited controls of similar ages to MUI participants because of the known age-dependent differences in the female vaginal microbiome and the potential influence of age upon the human microbiome in general [16,17]. Since the six DMM community-types differed by age, separate post hoc sub-analyses were performed in women < 51 and ≥ 51 years, the median age of menopause.¹⁸ Self-reported menopausal status was not used to discriminate community-types, as approximately 20% of women in this study did not know their menopausal status.

Overall alpha and beta diversity were compared between MUI and controls. Alpha-diversity (Shannon index as a measure of bacterial genus diversity within individuals) was evaluated using a similar linear mixed model to those described previously, with the following covariates: DMM community-type, MUI versus control, age, BMI, smoking status, and ethnicity. Beta-diversity (provides a measure of dissimilarity between individuals) was evaluated using ordination analysis, including Nonmetric Multidimensional Scaling distance-based redundancy analysis, and multivariate homogeneity of group dispersions [19–21]. Additionally, multivariate analysis of variance (MANOVA) association testing evaluated beta-diversity using the same covariates as the alpha-diversity model [22]

Results

Two hundred-twelve women (128 MUI, 84 controls) contributed specimens for this study from January 2015 through April 2016. DNA was successfully extracted, sequenced and analyzed from 97.6% (207/212) of the specimens (123/128 MUI, 84/84 controls). Participants' mean age was 53 years and did not differ between MUI and controls. MUI participants had higher mean BMI, were more commonly Hispanic, more commonly had recurrent UTIs, and more commonly used vaginal estrogen compared to controls (Table 1). Bacterial DNA sequencing resulted in a median sequencing read depth per sample of 80,949 reads (range 12,517–450,993). Bioinformatic processing of the 16S rRNA sequences resulted in the classification of 28 phyla, 60 classes, 82 orders, 191 families, and 581 genera.

The proportion of women with *Lactobacillus* predominant microbiota (>50% *Lactobacillus* in their samples) did not differ between MUI and controls [45/123 (36.6%), 36/84 (42.9%), $P=0.364$]. This was true for both younger and older women [< 51 years: 27/57 (47.4%) MUI; 20/38 (52.6%) controls, $P=0.615$; ≥ 51 years: 18/66 (27.3%) MUI, 16/46 (34.8%) controls, $P=0.395$]. Although *Lactobacillus* predominance did not distinguish between MUI and controls, its predominance differed between younger and older women overall, with higher *Lactobacillus* predominance in younger women [47/95 (49.5%) in < 51 years; 34/112 (30.4%) in ≥ 51 years, $P=0.005$].

DMM analysis identified six DMM community-types. Figure 1 qualitatively and quantitatively describes the composition of the six communities. In bivariate analysis, the proportion of women belonging to the DMM community-types differed between MUI and controls ($P=0.032$) (Table 1). Additional bivariate analyses of clinical characteristics found that DMM communities also differed in age and smoking status (Table 2).

On initial multivariable analysis higher BMI and Hispanic ethnicity remained significantly associated with MUI (Table 3). Although history of recurrent UTIs and the use of vaginal estrogen were significant on bivariate analysis, there were too few subjects in these groups to reliably include them as separate covariates in this model. There was no significant effect overall in community-type composition between MUI and controls ($P=0.196$) (Table 3). However, as bivariate analysis indicated that DMM communities varied by age, post hoc multivariable analysis of women < 51 years of age (controlling for DMM community-types, smoking status, ethnicity, age and BMI) revealed that DMM community-type and BMI remained associated with MUI (Table 4). In this multivariable model, the community with a very high proportion (89.2%) of *Lactobacillus* (*High-Lactobacillus* community-type 1, Fig. 1) served as the comparator community as it had the highest proportion of controls. In these younger women, those with the mixed genera community-type (*Mixed* community-type 2, Fig. 1), or those with the moderate *Lactobacillus* community-type (*Moderate-Lactobacillus* community-type 6, composed on average of 61.1% *Lactobacillus*, Fig. 1) had approximately 7 to 8-fold increased odds of having MUI (Table 4). Post-hoc multivariable analysis of women ≥ 51 years revealed that bacterial community-types did not differ between MUI and controls ($P=0.938$); only body mass index ($P=0.010$) remained independently associated with MUI (Appendix Table 1).

Alpha diversity (Shannon and Simpson Indexes) did not differ between MUI and controls, but did differ based on DMM community-types (Table 5). The *High-Lactobacillus* community-type 1 was the most homogeneous and least diverse, with all other community-types being more diverse ($p<0.001$). Beta diversity also did not differ between MUI and control groups (Appendix Figure 1).

Discussion

We found no difference in *Lactobacillus* predominance between women with MUI compared to similarly aged controls. However, analysis of community types resulting from DMM clustering of individuals into groups based on the entire composition of the urinary

microbiome revealed that several urinary bacterial communities significantly differed between MUI and controls in women < 51 years of age.

DMM methodology concomitantly uses the presence and abundance of all genera across both cases and controls to identify groups with similar microbial communities.^{14,15} This method accommodates data with rare or sparse genera, and varying numbers and types of identified genera across samples [14]. The DMM community-types, derived based on commonality of genera, served as independent variables in multivariable analysis along with clinical parameters such as age and BMI. Other clustering methods measure pairwise distances between observations based on a single metric derived from the differences in individual genera (for example, the maximum or minimum difference). Instead of using hierarchical clustering of individuals based on these metrics, we chose to use DMM methods to more fully account for the diversity and particular composition of the microbiome [14,15].

Six urinary community-types were identified by DMM analysis. Communities differed by age, smoking history and presence of MUI. We found that the *High-Lactobacillus* community (89% *Lactobacillus*) (community-type 1) had the largest proportion of asymptomatic controls while two other microbial communities were associated with MUI. In younger women, both BMI and specific DMM communities were associated with MUI. Compared to the *High-Lactobacillus* community-type 1, a *Mixed* (low-*Lactobacillus*, community-type 2) and a *Moderate-Lactobacillus* community-type 6 were associated with a 7 to 8-fold higher odds of MUI. These results are similar to another female urinary microbiome study, which noted that the UI microbiome was characterized by decreased *Lactobacillus* and increased *Gardnerella* abundance, characteristics comparable to our MUI *Mixed* DMM community-type 2 [4]. Thus, two research groups using different analytic techniques found congruent results in women with UI and MUI. These findings suggest that *Lactobacillus* may be associated with continence whereas *Gardnerella* may be associated with incontinence and the proportions or combinations of these bacteria may influence urinary symptoms, particularly in younger women.

In older women, only BMI, not microbiome communities, remained associated with MUI in multivariable analysis. The differential impact of age on urinary microbiome findings underscores the importance of recruitment of similarly aged, asymptomatic controls. The effect of age on microbial communities may contribute to treatment response and disease severity in UI. In the vaginal microbiome, *Lactobacillus* dominates the microbiota of premenopausal women (83%) compared to dominance in only 54% of post-menopausal women [16]. Similarly, the current study found that in the urinary microbiome, *Lactobacillus* dominance in women <51 was greater than in women ≥ 51 years. Although studies of the relationship between the urinary and vaginal microbiomes are scarce, the possibility of that the two microbiomes may be linked will be investigated in a planned future analysis.

A more recent culture-based study that compared women with overactive bladder and healthy controls also demonstrated differences in bacterial genera. *Lactobacillus* was found less commonly in women with overactive bladder [25]. Our study also found that a highly

predominant *Lactobacillus* community (*High-Lactobacillus*, community-type 1) was more common in controls, while women with MUI (*Mixed & Moderate-Lactobacillus*, community-types 2 & 6) more commonly had communities with lesser proportions of *Lactobacillus*. In aggregate, these studies support the concept that *Lactobacillus* may be associated with lack of urinary symptoms. Importantly, *Lactobacillus* abundance alone did not distinguish between absence and presence of urinary symptoms. The proportion of *Lactobacillus* as well as the combination of *Lactobacillus*, *Gardnerella* and other genera (such as *Prevotella*, *Serratia*, *Eschericia*, *Streptococcus*, *Tepidomonas*) may distinguish those with or without urinary symptoms. For example, despite the *Lactobacillus* predominance in the *Moderate-Lactobacillus* community-type 6, *Gardnerella*, in combination with other genera, more commonly represented MUI. The current study suggests that *Lactobacillus* occurrence or predominance may not be the only predictor of urinary symptoms, but that *Lactobacillus*, in addition to combinations and proportions of other bacterial taxa, may influence MUI communities and the MUI microbiome.

Thomas-White recently evaluated the microbiome of women undergoing SUI surgery and found no association between SUI symptoms and microbiome status [26]. The current study could not attribute the observed differences in the MUI microbiome to UII or SUI predominance, but findings from Thomas-White suggest that the driving influence on the MUI microbiome may be the UII component [26]. Those investigators also reported that UII symptoms were associated with BMI and menopausal status. Our findings, too, found that BMI and older age (as a reflection of menopausal status) were independently associated with MUI. Our study, similar to reports from Pearce [4] and Karstens [27], found that overall microbiome diversity measures did not differ between MUI and controls. We did find, however, that the community with the least alpha diversity (community-type 1), was most commonly found in controls whereas all other communities, including those representative of MUI (community-types 2 and 6), were more heterogeneous. This is consistent with microbiome studies from other body regions, which have reported that increasingly heterogeneous communities may be associated with disturbed habitats [14].

Strengths of this study include strategies to improve generalizability and minimize bias: rigorous definitions distinguishing MUI cases and controls, a well-characterized and age-matched asymptomatic control group recruited from multiple geographic sites, the use of state-of-the-art metagenomics, and masking of laboratory investigators to case/control status. The analysis was further strengthened by the use of DMM to decrease data dimensionality and facilitate multivariable analysis. Limitations include its analysis to the genus rather than species level; in our future work comparing the urinary and vaginal microbiomes we will analyse to the species level. The use of a group demarcation of 51 years may not precisely reflect age of menopause. We chose this cut-point because self-identified menopausal status was missing in approximately 20% of our participants and self-identification of menopause misclassifies 30–40% of women [28,29]. Finally, given that the analysis characterizing the MUI microbiome was complex and numbers within the final six DMM groups were relatively small, our findings will require confirmation by studies with larger cohorts.

In summary, *Lactobacillus* predominance did not differ between MUI and controls. We did find that although membership in distinct DMM communities did not distinguish between

MUI and controls overall, it did distinguish between MUI and controls in younger women < 51 years. Younger MUI participants more commonly had *Moderate-Lactobacillus* or *Mixed* communities rather than a *High-Lactobacillus* community. Whether the high preponderance of health-associated bacteria (*Lactobacillus*) or the shift in the balance of MUI-associated bacteria (e.g. *Gardnerella*, *Prevotella*) contributes to bladder symptoms warrants further investigation. Furthermore, whether these communities are found to be predictive of treatment success in these participants of the parent trial is yet to be determined [6].

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Funding Source & Sponsor's Role: The Eunice Kennedy Shriver National Institute of Child Health and Human Development sponsored this Pelvic Floor Disorders Network (PFDN) study (1-U10-HD069025-01, 2-U10-HD041261-11, 2-U10-HD041267-12, 1-U10-HD069013-01, 2-U10-HD054214-06, 2-U10-HD054215-06, 1-U10-HD069010-01, 1-U10-HD069006-01, 1-U10-HD069031-01). ClinicalTrials.gov number NCT01959347.

Other Support: National Center for Research Resources and the National Center for Advancing Translational Sciences of the National Institutes of Health (Grant Number ULTR001449, the University of New Mexico Clinical and Translational Science Center) (for performance of DNA extraction, 16S sequencing)

The authors would like to thank the research coordinators and all those who made this work possible, including: *University of Alabama at Birmingham*; R. Edward Varner MD, Robert L. Holley MD, David R. Ellington MD, Isuzu Meyer MD, Alison Parden MD, Alicia Ballard MD, Velria Willis BSN, Nancy Saxon BSN, Kathy Carter BSN. *Brown University*; Deborah Myers MD, Charles Rardin MD, Brittany Star Hampton MD, Cassandra Carberry MD, Kyle Wohlrab MD, Ann Meers BSN, Katheryn Rhodes BA. *Cleveland Clinic Foundation*; Matthew Barber MD, Marie Paraiso MD, Eric Jelovsek MD, Cecile Unger MD, Audra Hill MD, Ly Pung RN, Kathleen Dastoli RN, Annette Graham RN, Maryori Edington. *Duke University*; Cindy Amundsen MD, Anthony Visco MD, Alison Weidner MD, Amie Kawasaki MD, Shantae McLean, Nicole Longoria, Akira Hayes. *University of California San Diego*; Marianna Alperin MD, Michael Albo MD, Laura Aughinbaugh RNP, Joann Columbo, Cindy Furey PT, Sherella Johnson, Charles Nager MD, Patsy Riley RN. *Kaiser San Diego*; Shawn Menefee MD, Jasmine Tan-Kim MD, Keisha Dyer MD, Gouri Diwadkar MD, Karl Luber MD, Lynn Hall RNP, Gisselle Zazueta-Damian, Linda MacKinnon. *Kaiser Bellflower*; John N. Nguyen MD, Sharon Jakus-Walkman MD, Azadeh Rezvan MD, Christina Liao MD, Arty Patel PT, Mary Simmons PT, Mercedes Cardona, Nancy Flores. *University of New Mexico*; Gena Dunivan MD, Peter Jeppson MD, Sara Cichowski MD, Karen Taylor BA, Cassandra Castaneda BA, Julia Middendorf BSN, Susan Tigert BA/BS, Kurt Schwalm BS, Amy Overby BS, CG/MB/PA(ASCP)CM. *University of Pennsylvania*; Heidi Harvie MD, Uduak Andy MD, Lorraine Flick, Michelle Kinglee. *University of Pittsburgh*; Pamela Moalli PhD, MD, Michael Bonidie, Gary Sutkin MD, Jonathan Shepherd MD, Christopher Chermansky MD, Judy Gruss, Karen Mislanovich, Lori Geraci. *RTI International*; Dennis Wallace PhD, Carolyn Huitema MS, Michael Ham BS, Joshua Levy MS.

References

1. Minassian VA, Bazi T, Stewart WF. Clinical epidemiological insights into urinary incontinence. *International urogynecology journal*. 2017; 28:687–96.2. [PubMed: 28321473]
2. Sung VW, Borello-France D, Dunivan G, et al. Methods for a multicenter randomized trial for mixed urinary incontinence: rationale and patient- centeredness of the ESTEEM trial. *International urogynecology journal*. 2016; 27:1479–90. [PubMed: 27287818]
3. Brubaker L, Wolfe AJ. The Female Urinary Microbiota/Microbiome: Clinical and Research Implications. *Rambam Maimonides Med J*. 2017;8.
4. Pearce MM, Hilt EE, Rosenfeld AB, et al. The female urinary microbiome: a comparison of women with and without urgency urinary incontinence. *mBio*. 2014; 5:e01283–14. [PubMed: 25006228]
5. Thomas-White KJ, Hilt EE, Fok C, et al. Incontinence medication response relates to the female urinary microbiota. *International urogynecology journal*. 2016; 27:723–33. [PubMed: 26423260]

6. Komesu YM, Richter HE, Dinwiddie DL, et al. Methodology for a vaginal and urinary microbiome study in women with mixed urinary incontinence. *International urogynecology journal*. 2017; 28:711–20. [PubMed: 27738739]
7. Shumaker SA, Wyman JF, Uebersax JS, McClish D, Fantl JA. Health-related quality of life measures for women with urinary incontinence: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. *Continence Program in Women (CPW) Research Group. Qual Life Res*. 1994; 3:291–306. [PubMed: 7841963]
8. Coyne KS, Margolis MK, Bavendam T, Roberts R, Elinoff V. Validation of a 3-item OAB awareness tool. *International journal of clinical practice*. 2011; 65:219–24. [PubMed: 21235701]
9. Sandvik H, Seim A, Vanvik A, Hunskaar S. A severity index for epidemiological surveys of female urinary incontinence: comparison with 48-hour pad-weighing tests. *Neurourology and urodynamics*. 2000; 19:137–45. [PubMed: 10679830]
10. Kumar PS, Brooker MR, Dowd SE, Camerlengo T. Target region selection is a critical determinant of community fingerprints generated by 16S pyrosequencing. *PLoS one*. 2011; 6(6):e20956. [PubMed: 21738596]
11. Nelson DE, Dong Q, Van Der Pol B, Toh E, Fan B, Katz BP, Mi D, Rong R, Weinstock GM, Sodergren E, Fortenberry JD. Bacterial Communities of the Coronal Sulcus and Distal Urethra of Adolescent Males. *PLoS One*. 2012; 7(5):e36298. [PubMed: 22606251]
12. Wolfe AJ, Toh E, Shibata N, Rong R, Kenton K, FitzGerald MP, et al. Evidence of Uncultivated Bacteria in the Adult Female Bladder. *J Clin Microbiol*. 2012; 50:1376–83. [PubMed: 22278835]
13. Wang, Qiong; Garrity, George M; Tiedje, James M; Cole, James R. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. *Applied and environmental microbiology*. 73(16)2007; :5261–5267. [PubMed: 17586664]
14. Holmes I, Harris K, Quince C. Dirichlet Multinomial Mixtures: Generative Models for Microbial Metagenomics. *PLoS On3*. 2012; 7(2):e30126.
15. La Rosa PS, Brooks JP, Deych E, Boone EL, Edwards DJ, Wang Q, et al. Hypothesis Testing and Power Calculations for Taxonomic-Based Human Microbiome Data. *PLoS ONE*. 2012; 7(12):e52708.
16. Brotman RM, Shardel MD, Gajer P, Fadrosh D, Change K, Silver MI, et al. Association between the vaginal microbiota, menopause status and signs of vulvovaginal atrophy. *Menopause*. 2013; 21(5):1–9.
17. Whiteside SA, Razvi H, Dave S, Reid G, Burton JP. The microbiome of the urinary tract—a role beyond infection. *Nat Rev Urol*. 2015; 12:81–90. [PubMed: 25600098]
18. ACOG Practice Bulletin No. 141: management of menopausal symptoms. *Obstetrics and gynecology*. 2014; 123:202–16. [PubMed: 24463691]
19. Minchin PR. An Evaluation of the Relative Robustness of Techniques for Ecological Ordination. *Vegetatio*. 1987; 69:89–107.
20. Legendre P, Anderson MJ. Distance-based redundancy analysis: Testing multispecies responses in multifactorial ecological experiments (vol 69, pg 1, 1999). *Ecol Monogr*. 1999; 69:512–12.
21. Anderson MJ. A new method for non-parametric multivariate analysis of variance. *Austral Ecol*. 2006; 26:32–46.
22. Anderson MJ. Permutation tests for univariate or multivariate analysis of variance and regression. *Can J Fish Aquat Sci*. 2001; 58:626–39.
23. Ravel J, Gajer P, Abdo Z, et al. Vaginal microbiome of reproductive-age women. *Proc Natl Acad Sci U S A*. 2011; 108(Suppl 1):4680–7. [PubMed: 20534435]
24. La Rosa PS, Brooks JP, Deych E, Boone EL, Edwards DJ, Wang Q, et al. Hypothesis Testing and Power Calculations for Taxonomic-Based Human Microbiome Data. *PLoS ONE*. 2012; 7(12):e52708.
25. Curtiss N, Balachandran A, Krska L, Peppiatt-Wildman C, Wildman S, Duckett J. A case controlled study examining the bladder microbiome in women with Overactive Bladder (OAB) and healthy controls. *European journal of obstetrics, gynecology, and reproductive biology*. 2017; 214:31–35.

26. Thomas-White KJ, Kliethermes S, Rickey L, et al. Evaluation of the urinary microbiota of women with uncomplicated stress urinary incontinence. *American journal of obstetrics and gynecology*. 2017; 216:55 e1–55 e16. [PubMed: 27498309]
27. Karstens L, Asquith M, Davin S, Stauffer P, Fair D, Gregory WT, et al. Does the Urinary Microbiome Play a Role in Urgency Urinary Incontinence and Its Severity? *Front Cell Infect Microbiol*. 2016; 6(78):1–13. [PubMed: 26870699]
28. Kroke A, Schulz M, Hoffman K, Bermann MM, Boeing H. Assignment to menopausal status and estimation of age at menopause for women with missing or invalid data---a probabilistic approach with weighting factors in a large-scale epidemiologic study. *Maturitas*. 2001; 40:39–46. [PubMed: 11684371]
29. Harlow SD, Crawford SL, Sommer B, Greendale GA. Self-defined menopausal status in a multi-ethnic sample of midlife women. *Maturitas*. 2000; 36:93–122. [PubMed: 11006497]

Figure 1.
Bacterial Communities (1–6) Comparing Mixed Urinary Incontinence to Controls including and Microbiota Components

Table 1Baseline Characteristics of MUI and Control Participants (Bivariate Analysis^a)

Variable	Category	Study Group		p-value
		MUI (N = 123)	Control (N = 84)	
Age - Mean (SD)		53.0 (10.8)	53.0 (11.7)	0.983
BMI - Mean (SD)		32.7 (7.1)	28.4 (6.6)	<.001
Race - N (%)	American Indian or Alaska Native	2 (1.6)	1 (1.2)	0.797
	Asian	1 (0.8)	0 (0.0)	0.407
	Black or African American	16 (13.0)	19 (22.6)	0.070
	White	91 (74.0)	64 (76.2)	0.719
	Other	14 (11.4)	2 (2.4)	0.017
Ethnicity - N (%)	Hispanic or Latina	28 (22.8)	6 (7.1)	0.011
	Not Hispanic or Not Latina	93 (75.6)	77 (91.7)	
	Unknown	2 (1.6)	1 (1.2)	
Smoking status - N (%)	Never smoked	71 (57.7)	55 (65.5)	0.549
	Quit smoking <6 mo.	2 (1.6)	2 (2.4)	
	Quit smoking >6 mo.	35 (28.5)	21 (25.0)	
	Currently smoking	15 (12.2)	6 (7.1)	
3 or more UTI in past year - N (%)		12 (9.8)	0 (0.0)	0.003
Ever Pregnant - N (%)		116 (94.3)	73 (86.9)	0.063
Menstrual Status - N (%)	Pre-menopausal	36 (29.3)	25 (29.8)	0.830
	Post-menopausal	64 (52.0)	46 (54.8)	
	Not sure	23 (18.7)	13 (15.5)	
Lactobacillus Predominance - N (%)		45 (36.6)	36 (42.9)	0.364
Estrogen by prescription - N (%)	Oral	10 (8.1)	6 (7.1)	0.794
	Skin Patch	5 (4.1)	4 (4.8)	0.809
	Vaginal Cream/Tablets	21 (17.1)	3 (3.6)	0.003
	None	89 (72.4)	69 (82.1)	0.104
Dirichlet Multinomial Mixture Community- N (%)	Overall Community Comparisons			0.032

	Variable	Category	Study Group		p-value
			MUI (N = 123)	Control (N = 84)	
		Community 1	11 (8.9)	19 (22.6)	
		Community 2	34 (27.6)	16 (19.0)	
		Community 3	16 (13.0)	16 (19.0)	
		Community 4	17 (13.8)	13 (15.5)	
		Community 5	6 (4.9)	4 (4.8)	
		Community 6	39 (31.7)	16 (19.0)	

^aChi-Squared tests or ANOVA

Demographic and Clinical Variables of DMIM^a Community Types (Bivariate Analysis)^b

Table 2

Variable	Category	DMIM Community (Cmty)						p-value
		Cmty 1 (N = 30)	Cmty 2 (N = 50)	Cmty 3 (N = 32)	Cmty 4 (N = 30)	Cmty 5 (N = 10)	Cmty 6 (N = 55)	
Study Group - N (%)	MUI	11 (36.7)	34 (68.0)	16 (50.0)	17 (56.7)	6 (60.0)	39 (70.9)	0.032
	Control	19 (63.3)	16 (32.0)	16 (50.0)	13 (43.3)	4 (40.0)	16 (29.1)	
Age - Mean (SD)		49.8 (9.4)	56.8 (11.7)	55.5 (12.0)	55.3 (12.7)	51.8 (9.3)	48.8 (8.8)	0.001
BMI - Mean (SD)		29.7 (6.1)	30.9 (7.5)	29.6 (6.5)	29.3 (7.3)	31.2 (7.1)	33.3 (7.4)	0.080
Race - N (%)	American Indian or Alaska Native	0 (0.0)	1 (2.0)	1 (3.1)	0 (0.0)	0 (0.0)	1 (1.8)	0.873
	Asian	1 (3.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0.313
	Black or African American	6 (20.0)	9 (18.0)	5 (15.6)	4 (13.3)	1 (10.0)	10 (18.2)	0.966
	White	23 (76.7)	33 (66.0)	25 (78.1)	23 (76.7)	8 (80.0)	43 (78.2)	0.725
	Other	0 (0.0)	7 (14.0)	3 (9.4)	3 (10.0)	1 (10.0)	2 (3.6)	0.222
Ethnicity - N (%)	Hispanic or Latina	2 (6.7)	12 (24.0)	4 (12.5)	6 (20.0)	2 (20.0)	8 (14.5)	0.701
	Not Hispanic or Not Latina	28 (93.3)	37 (74.0)	28 (87.5)	23 (76.7)	8 (80.0)	46 (83.6)	
	Unknown	0 (0.0)	1 (2.0)	0 (0.0)	1 (3.3)	0 (0.0)	1 (1.8)	
Smoking status - N (%)	Never smoked	15 (50.0)	30 (60.0)	25 (78.1)	24 (80.0)	4 (40.0)	28 (50.9)	<.001
	Quit smoking <6 mo.	1 (3.3)	1 (2.0)	0 (0.0)	0 (0.0)	2 (20.0)	0 (0.0)	
	Quit smoking >6 mo.	11 (36.7)	18 (36.0)	6 (18.8)	3 (10.0)	1 (10.0)	17 (30.9)	
	Currently smoking	3 (10.0)	1 (2.0)	1 (3.1)	3 (10.0)	3 (30.0)	10 (18.2)	
3 or more UTI in past year - N (%)		1 (3.3)	5 (10.0)	1 (3.1)	0 (0.0)	0 (0.0)	5 (9.1)	0.314
Ever Pregnant - N (%)		26 (86.7)	48 (96.0)	28 (87.5)	26 (86.7)	9 (90.0)	52 (94.5)	0.500
Menstrual Status - N (%)	Pre-menopausal	10 (33.3)	10 (20.0)	8 (25.0)	7 (23.3)	2 (20.0)	24 (43.6)	0.067
	Post-menopausal	13 (43.3)	34 (68.0)	20 (62.5)	19 (63.3)	5 (50.0)	19 (34.5)	
	Not sure	7 (23.3)	6 (12.0)	4 (12.5)	4 (13.3)	3 (30.0)	12 (21.8)	
Estrogen by prescription - N (%)	Oral	2 (6.7)	4 (8.0)	4 (12.5)	1 (3.3)	0 (0.0)	5 (9.1)	0.720
	Skin Patch	1 (3.3)	2 (4.0)	2 (6.3)	2 (6.7)	0 (0.0)	2 (3.6)	0.937
	Vaginal Cream/Tablets	4 (13.3)	9 (18.0)	2 (6.3)	3 (10.0)	1 (10.0)	5 (9.1)	0.636

Variable	Category	DMM Community (Cmty)					p-value
		Cmty 1 (N = 30)	Cmty 2 (N = 50)	Cmty 3 (N = 32)	Cmty 4 (N = 30)	Cmty 5 (N = 10)	
	None	23 (76.7)	36 (72.0)	23 (71.9)	23 (76.7)	9 (90.0)	0.804

^aDirichlet Multinomial Mixture

^bChi-Squared tests or ANOVA

Multivariable Model Comparison of MUI & Controls Including DMM^a Communities and Demographics

Table 3

Model Term	P-value for Effect	Comparison	Estimated Odds Ratio	95% Confidence Interval	P-value for Comparison
Age	0.555	Age (increase of 5 years)	1.06	(0.87, 1.28)	
BMI	<0.001 ^c	BMI (increase of 5 kg/m ²)	1.56	(1.22, 1.98)	
DMM Community Type	0.196	DMM Community 2 vs. DMM Community 1	2.99	(1.06, 8.47)	0.039^c
		DMM Community 3 vs. DMM Community 1	1.73	(0.57, 5.26)	0.334
		DMM Community 4 vs. DMM Community 1	2.15	(0.69, 6.75)	0.188
		DMM Community 5 vs. DMM Community 1	2.19	(0.46, 10.43)	0.323
		DMM Community 6 vs. DMM Community 1	3.51	(1.29, 9.59)	0.014^c
Smoking status	0.754	Never Smoked vs. Ever Smoked	1.11	(0.57, 2.18)	
Ethnicity ^b	0.013^c	Hispanic/Latina vs. Not Hispanic/Latina	3.59	(1.31, 9.83)	

^aDirichlet Multinomial Mixture^bSubjects with unknown ethnicity were combined with the non-Hispanic group.^cEffect or comparison was significant at the 0.05 level of significance.

Table 4

Multivariable Model Comparison of MUI & Controls, Including DMM^a Communities & Demographics in Women <51 years

Model Term	P-value for Effect	Comparison	Estimated Odds Ratio	95% Confidence Interval	P-value for Comparison ^d
Age	0.861	Age (increase of 5 years)	0.96	(0.61, 1.52)	
BMI	0.012^c	BMI (increase of 5 kg/m ²)	1.57	(1.11, 2.24)	
DMM Community Type	0.041^c	DMM Community 2 vs. DMM Community 1	7.10	(1.32, 38.10)	0.023^c
		DMM Community 3 vs. DMM Community 1	1.86	(0.32, 10.81)	0.487
		DMM Community 4 vs. DMM Community 1	1.38	(0.23, 8.42)	0.725
		DMM Community 5 vs. DMM Community 1	6.00	(0.46, 78.25)	0.169
		DMM Community 6 vs. DMM Community 1	7.78	(1.85, 32.62)	0.006^c
Smoking status	0.347	Never Smoked vs. Ever Smoked	1.65	(0.58, 4.69)	
Ethnicity ^b	0.104	Hispanic/Latina vs. Not Hispanic/Latina	3.25	(0.78, 13.51)	

^aDirichlet Multinomial Mixture

^bSubjects with unknown ethnicity were combined with the non-Hispanic group.

^cEffect or comparison was significant at the 0.05 level of significance.

^dP-value for comparison with *Hi-Lac* group (community 1), which had the highest level of *Lactobacillus* and highest proportion of control participants

Table 5

Alpha Diversity Measures of Urinary Microbiome

Metric	Total [mean (SD)]	MUI (N=123)			Control (N=84)			P-value of Comparison ^b	
		Mean (SD)	Min-Max		Mean (SD)	Min-Max		MUI vs. Control	DMM ^a Community Type
Shannon index	1.89 (0.90)	1.89 (0.86)	0.25–3.52		1.89 (0.96)	0.31–3.80		0.462	<0.001 ^c
Simpson index	0.63 (0.24)	0.64 (0.22)	0.07–0.94		0.61 (0.26)	0.08–0.95		0.485	<0.001 ^c

^aDirichlet Multinomial Mixture

^bp-values come from multivariable models which included terms for MUI/Control status, age, BMI, DMM community, type, ethnicity, and smoking status.

^cEffect or comparison was significant at the 0.05 level of significance.

Appendix Table 1

Multivariable Model Comparison of MUI & Controls Including DMM^a Communities & Demographics in Women 51 years

Model Term	P-value for Effect	Comparison	Estimated Odds Ratio	95% Confidence Interval	P-value for Comparison ^d
Age	0.793	Age (increase of 5 years)	1.04	(0.78, 1.39)	
BMI	0.010^c	BMI (increase of 5 kg/m ²)	1.65	(1.13, 2.41)	
DMM Community Type	0.938	DMM Community 2 vs. DMM Community 1	1.62	(0.39, 6.74)	0.503
		DMM Community 3 vs. DMM Community 1	1.31	(0.29, 5.98)	0.721
		DMM Community 4 vs. DMM Community 1	2.18	(0.45, 10.49)	0.329
		DMM Community 5 vs. DMM Community 1	0.99	(0.11, 8.63)	0.995
		DMM Community 6 vs. DMM Community 1	1.29	(0.29, 5.70)	0.734
		Never Smoked vs. Ever Smoked	0.94	(0.37, 2.36)	
Smoking status	0.892				
Ethnicity ^b	0.060	Hispanic/Latina vs. Not Hispanic/Latina	4.81	(0.94, 24.71)	

^aDirichlet Multinomial Mixture

^bSubjects with unknown ethnicity were combined with the non-Hispanic group.

^cEffect or comparison was significant at the 0.05 level of significance.

^dP-value for comparison with *Hfi-Lac* group (community 1), which had the highest level of *Lactobacillus* and highest proportion of control participants